Author

Sander B. Frank

Fred Hutch Cancer CenterORCID 0000-0001-7591-944XUnclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Assay:proteomics· 1 Assay:whole-genome sequencing· 1

Frequent Co-Authors

Colm M. MorrisseyiD· 2 shared Ilsa M. ColemaniD· 2 shared Michael C. HaffneriD· 2 shared Peter S. NelsoniD· 2 shared Ruth F. DumpitiD· 2 shared Armand Bankhead· 1 shared Brian P. HanrattyiD· 1 shared Bruce MontgomeryiD· 1 shared

Activity by Year

2024-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Colm M. MorrisseyORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyJournal of Clinical InvestigationPeer-reviewedJun 23, 2026

Genotoxic antibody-drug conjugates combined with Bcl-xL inhibitors enhance therapeutic efficacy in metastatic castration-resistant prostate cancer

Galina Semenova, Sander B. Frank, Ruth F. Dumpit…·John K. Lee

1 citation

humanproteomics

Cancer BiologybioRxivPreprintJul 16, 2024

Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies

Sander B. Frank, Thomas W. Persse, I. M. Coleman…·Peter S. Nelson

This study shows that acute CDK12 loss in prostate cancer causes HR deficiency via polyadenylation, but chronic loss leads to adaptation, making PARP inhibitors ineffective and suggesting CDK13 targeting as a new therapeutic approach.

3 citations

humanwhole-genome sequencing